Ahmet Turan Isik1, Pinar Soysal2, Adnan Yay3, Cansu Usarel2. 1. Center for Aging Brain and Dementia, Department of Geriatric Medicine, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey. Electronic address: atisik@yahoo.com. 2. Center for Aging Brain and Dementia, Department of Geriatric Medicine, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey. 3. Department of Internal Medicine, Izmir Military Hospital, Izmir, Turkey.
Abstract
AIMS: The present study aimed to evaluate effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4I), on cognitive functions in elderly diabetic patients with and without cognitive impairment. METHODS: 253 elderly patients with type 2DM, were enrolled in this prospective and observational study. After comprehensive geriatric assessment, the patients were divided into either sitagliptin or non-sitagliptin group. RESULTS: A total of 205 patients who completed the study (52 with Alzheimer's Disease (AD)) were re-evaluated 6months later. Sixth-month evaluation revealed no difference between sitagliptin and non-sitagliptin groups in terms of weight, body mass index, and HbA1c (p>0.05). However, the number of patients that required reduced insulin dose was significantly higher in the sitagliptin group (p=0.01). Sitagliptin therapy was associated with an increase in the Mini-Mental State Examination (MMSE) scores (p=0.034); patients without AD receiving only sitagliptin or insulin showed higher MMSE scores as compared to the patients receiving metformin alone (p=0.024). Likewise, the change in MMSE scores in AD patients receiving sitagliptin was significant and indicated improvement as compared to the patients receiving metformin (p=0.047). CONCLUSION: Besides its effects similar to those of insulin and metformin in glycemic control and in reducing need for insulin, 6-month sitagliptin therapy may also associated with improvement of cognitive function in elderly diabetic patients with and without AD. Further randomized controlled trials are needed to support these results.
AIMS: The present study aimed to evaluate effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4I), on cognitive functions in elderly diabeticpatients with and without cognitive impairment. METHODS: 253 elderly patients with type 2DM, were enrolled in this prospective and observational study. After comprehensive geriatric assessment, the patients were divided into either sitagliptin or non-sitagliptin group. RESULTS: A total of 205 patients who completed the study (52 with Alzheimer's Disease (AD)) were re-evaluated 6months later. Sixth-month evaluation revealed no difference between sitagliptin and non-sitagliptin groups in terms of weight, body mass index, and HbA1c (p>0.05). However, the number of patients that required reduced insulin dose was significantly higher in the sitagliptin group (p=0.01). Sitagliptin therapy was associated with an increase in the Mini-Mental State Examination (MMSE) scores (p=0.034); patients without AD receiving only sitagliptin or insulin showed higher MMSE scores as compared to the patients receiving metformin alone (p=0.024). Likewise, the change in MMSE scores in ADpatients receiving sitagliptin was significant and indicated improvement as compared to the patients receiving metformin (p=0.047). CONCLUSION: Besides its effects similar to those of insulin and metformin in glycemic control and in reducing need for insulin, 6-month sitagliptin therapy may also associated with improvement of cognitive function in elderly diabeticpatients with and without AD. Further randomized controlled trials are needed to support these results.
Authors: Peter Riederer; Amos D Korczyn; Sameh S Ali; Ovidiu Bajenaru; Mun Seong Choi; Michael Chopp; Vesna Dermanovic-Dobrota; Edna Grünblatt; Kurt A Jellinger; Mohammad Amjad Kamal; Warda Kamal; Jerzy Leszek; Tanja Maria Sheldrick-Michel; Gohar Mushtaq; Bernard Meglic; Rachel Natovich; Zvezdan Pirtosek; Martin Rakusa; Melita Salkovic-Petrisic; Reinhold Schmidt; Angelika Schmitt; G Ramachandra Sridhar; László Vécsei; Zyta Beata Wojszel; Hakan Yaman; Zheng G Zhang; Tali Cukierman-Yaffe Journal: J Neural Transm (Vienna) Date: 2017-08-01 Impact factor: 3.575
Authors: Stephen C Cunnane; Mark J Millan; Eugenia Trushina; Cecilie Morland; Alessandro Prigione; Gemma Casadesus; Zane B Andrews; M Flint Beal; Linda H Bergersen; Roberta D Brinton; Suzanne de la Monte; Anne Eckert; Jenni Harvey; Ross Jeggo; Jack H Jhamandas; Oliver Kann; Clothide Mannoury la Cour; William F Martin; Gilles Mithieux; Paula I Moreira; Michael P Murphy; Klaus-Armin Nave; Tal Nuriel; Stéphane H R Oliet; Frédéric Saudou; Mark P Mattson; Russell H Swerdlow Journal: Nat Rev Drug Discov Date: 2020-07-24 Impact factor: 84.694